[go: up one dir, main page]

WO1992021333A3 - Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors - Google Patents

Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors Download PDF

Info

Publication number
WO1992021333A3
WO1992021333A3 PCT/US1992/003702 US9203702W WO9221333A3 WO 1992021333 A3 WO1992021333 A3 WO 1992021333A3 US 9203702 W US9203702 W US 9203702W WO 9221333 A3 WO9221333 A3 WO 9221333A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
monoamine oxidase
withdrawal symptoms
type
craving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1992/003702
Other languages
French (fr)
Other versions
WO1992021333A2 (en
Inventor
George W Belendiuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Supernus Pharmaceuticals Inc
Original Assignee
Pharmavene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmavene Inc filed Critical Pharmavene Inc
Publication of WO1992021333A2 publication Critical patent/WO1992021333A2/en
Publication of WO1992021333A3 publication Critical patent/WO1992021333A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Methods of treating withdrawal symptoms and preventing or reducing craving of addictive psychostimulants (e.g., cocaine), addictive opiates, alcohol, or nicotine by administering to a patient a Type B monoamine oxidase inhibitor in an amount effective to alleviate withdrawal symptoms and prevent or reduce craving of addictive psychostimulants, addictive opiates, alcohol, or nicotine. A preferred Type B monoamine oxidase inhibitor is L-deprenyl, or selegiline.
PCT/US1992/003702 1991-05-24 1992-05-04 Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors Ceased WO1992021333A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70508591A 1991-05-24 1991-05-24
US705,085 1991-05-24

Publications (2)

Publication Number Publication Date
WO1992021333A2 WO1992021333A2 (en) 1992-12-10
WO1992021333A3 true WO1992021333A3 (en) 1993-01-07

Family

ID=24831978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/003702 Ceased WO1992021333A2 (en) 1991-05-24 1992-05-04 Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors

Country Status (2)

Country Link
AU (1) AU1992592A (en)
WO (1) WO1992021333A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9974752B2 (en) 2014-10-31 2018-05-22 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713087B1 (en) * 1993-11-30 1996-02-23 Saurat Jean Hilaire Use of selegiline and its derivatives for the preparation of a medicament intended for the treatment of psoriasis.
DE4428444A1 (en) * 1994-08-11 1996-02-15 Dresden Arzneimittel Use of selegiline for the treatment of epileptic disorders
US6299901B1 (en) 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
WO1996024346A1 (en) * 1995-02-10 1996-08-15 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
NZ309980A (en) 1995-06-07 2001-06-29 Noven Pharma Transdermal composition containing a blend of one or more polymers, one or more drugs that has a low molecular weight and is liquid at room temperature
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
DE19746191C2 (en) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Method of using an active ingredient-containing patch to combat or alleviate addiction
US6210705B1 (en) * 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US7083808B2 (en) 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
AU2002354017B2 (en) 2001-11-05 2007-08-16 Krele Pharmaceuticals, Inc. Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
AU2003250106B2 (en) 2002-07-18 2009-11-26 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
EP2433626B1 (en) 2003-11-25 2015-11-04 Technion Research & Development Foundation Ltd. Compositions and methods for treatment of cardiovascular disorders and diseases
US8263655B2 (en) 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
DE102006038719A1 (en) 2006-08-18 2008-02-21 Tesa Ag Pressure-sensitive adhesive strips for moisture-resistant, removable adhesive bonds
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (en) 2006-11-30 2012-05-15 Probiodrug Ag NEW INHIBITORS OF GLUTAMINYL CYCLASE
EA200901140A1 (en) 2007-03-01 2010-04-30 Пробиодруг Аг NEW USE OF GLUTAMINYL CYCLLASE INHIBITORS
JP5667440B2 (en) 2007-04-18 2015-02-12 プロビオドルグ エージー Thiourea derivatives as glutaminyl cyclase inhibitors
CN102695546B (en) 2009-09-11 2014-09-10 前体生物药物股份公司 Heterocylcic derivatives as inhibitors of glutaminyl cyclase
RU2607595C2 (en) 2010-02-03 2017-01-10 Фарма Ту Б Лтд. Rasagiline compositions of prolonged release and use thereof
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
JP5945532B2 (en) 2010-04-21 2016-07-05 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
KR20130132774A (en) * 2010-09-01 2013-12-05 토닉스 파마슈티컬스, 아이엔씨. Treatment for cocaine addiction
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
US9937144B2 (en) 2013-01-30 2018-04-10 The Johns Hopkins University Treatment of drug abuse by preventing GAPDH nitrosylation
PL3461819T3 (en) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitors of glutaminyl cyclase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEMENTIA, Vol. 1 (6), 1990, KABINS, DARRYL AND SAMUEL GERSHON, "Potential Applications for Monoamine Oxidase B Inhibitors, pp. 323-348. *
MED. CLIN. N. AM., Vol. 72(4), 1988, KRANZLER, H.R. AND N.R. LIEBOWITZ, "Anxiety and Depression in Substance Abuse", pp. 867-885. *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10507186B2 (en) 2014-10-31 2019-12-17 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10111839B2 (en) 2014-10-31 2018-10-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10292939B2 (en) 2014-10-31 2019-05-21 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10292938B2 (en) 2014-10-31 2019-05-21 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10449159B2 (en) 2014-10-31 2019-10-22 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10500162B2 (en) 2014-10-31 2019-12-10 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US9974752B2 (en) 2014-10-31 2018-05-22 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10512613B2 (en) 2014-10-31 2019-12-24 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10512612B2 (en) 2014-10-31 2019-12-24 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10568841B2 (en) 2014-10-31 2020-02-25 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10688060B2 (en) 2014-10-31 2020-06-23 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US11896722B2 (en) 2014-10-31 2024-02-13 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Also Published As

Publication number Publication date
AU1992592A (en) 1993-01-08
WO1992021333A2 (en) 1992-12-10

Similar Documents

Publication Publication Date Title
WO1992021333A3 (en) Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
CA2181048A1 (en) A method for sustained and extended corneal analgesia
EP1555025A3 (en) Use of dehydroepiandrosterone analogs for the treatment of asthma
GB9106678D0 (en) Wound healing
NO923859L (en) DRUG
LU92613I2 (en) Saxagliptin and its pharmaceutically acceptable derivatives (ONGLYZA)
CA2129541A1 (en) Method of Promoting Nitrogen Retention in Humans
GR3030041T3 (en) Prolonged activity nicotine patch
CA2245661A1 (en) Multiple sclerosis treatment
AU7807791A (en) Method of treating impotence
CA2251966A1 (en) Transdermally administered dextromethorphan as antitussive agent
DE69326459D1 (en) ACTIVE SUBSTANCES FOR TREATING ADDICTIVE DISEASES
PT659082E (en) USE OF CYTOCHROME INHIBITORS P450 TO INHIBIT THE METABOLISM OF ACRIDINE SUBSTITUTE WITH NITROGEN
JPS6483020A (en) Medicinal composition for preventing or treating aids
IE881115L (en) Inhibitors of angiogenin
Suedfeld et al. Restricted environmental stimulation therapy of smoking: A parametric study
AU1777595A (en) Methods for treating neurofibromatosis
EP0397211A3 (en) Percutaneous administration of 3'-azide-3'-deoxythymidine
NO950599L (en) Method of inhibiting HIV replication using IL-4
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
EP0286802A3 (en) Use of ofloxacin in treating or preventing locally periodontal disease
Carlson Supersensitivity to apomorphine and stress two years after chronic methadone treatment
Kontoes A study of the effect of morphine and methadone on the enzymic system of the protozoan Tetrahymena pyriformis. A possible explanation of the abstinence syndrome induced by opiates.
RU94042516A (en) Method of opium abstinent syndrome arresting
Borg et al. Cocaine abuse is decreased with effective methadone maintenance treatment at an urban Department of Veterans Affairs (DVA) Program

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase